AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05045950 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: WBRT utilizing the PRDR technique
Description: The total dose of 3000 cGy (30 Gy) will be divided 10 fractions of 300 cGy (3 Gy); each fraction will be delivered as a series of 20 cGy (0.2Gy) pulses separated by 3 min time intervals. 20 cGy / 3 min = 6.67 cGy/min (or 0.0667 Gy/min). Total time is determined by the fractionated series and time intervals, meaning 300cGy/20cGy = 15 division x 3 minutes = 45 minutes. Including time to set up, approximate total time per treatment session will be 60 minutes.
Study NCT06235255 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Imagery
Description: The participant will complete the Guided Imagery Intervention for 21 consecutive days.
Study NCT06235255 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Power Intervention
Description: The investigator with the subject uses the power profile generated by the PKPCT to generate goals that will positively affect functional health.
Study NCT06235255 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Guided Imagery and Cognitive Power Intervention
Description: This intervention is a combination of the Guided Imagery Intervention in tandem with the Cognitive Power Intervention
Study NCT05063071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide 25 MG
Description: After orthotopic liver transplant, all patients will receive Tenofovir Alafenamide monotherapy without HBIG for HBV Prophylaxis.
Study NCT06273137 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive affect treatment
Description: PAT includes 15 weekly, 1-hour sessions. The treatment is composed of three modules targeting behaviors (Sessions 1-7), cognitions (Sessions 8 -10), and compassion (Sessions 11-14), with skills being reinforced in a cumulative manner in subsequent sessions. The final session in the original treatment (Session 15) addressed relapse prevention, which will be adapted to focus on further reinforcing and generalizing learned skills. The treatment includes guided activities that target different aspects of positive affectivity such as reward approach-motivation, reward learning, and reward attainment.
Study NCT04835831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: adapted physical activity + Dietetic advice
Description: adapted physical activity during 24 weeks
Study NCT05375773 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PVP-I Nasal Irrigation and gargling
Description: The solution is prepared by the researcher, which contains 0.5% PVP-I and 2.27% hypertonic saline
Study NCT05551442 — intervention group
Intervention type: PROCEDURE
Intervention: To explore the comparative study of different positioning methods in robot assisted laparoscopic pyeloplasty.
Description: The incidence of surgical positioning time and secondary berths, surgical time, intraoperative blood loss and intraoperative complications were compared among the three groups.
Study NCT05551442 — intervention group
Intervention type: DEVICE
Intervention: To discuss the comparative study of different position placement methods of renal pelvis ureteroplasty on the Da Vinci robotic Xi platform
Description: To discuss the comparative study of different position placement methods of renal pelvis ureteroplasty on the Da Vinci robotic Xi platform
Study NCT06403488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: specific aromatase inhibitor
Study NCT05767476 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical and instrumental neurological assessment
Description: Participants will be involved in serial assessment:~* Neonatal Cranial Ultrasonography~* Brain magnetic resonance imaging~* Neurological assessment~* Neurodevelopmental and cognitive assessment~* Electroencephalogram (EEG)~* Motor performance assessment
Study NCT06005129 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personality-Based Therapy
Description: Participants will be randomized to a 2- or 4-week assessment-only baseline period. After the baseline period, participants will receive the personality-based treatment module corresponding to their highest clinical elevation (i.e., neuroticism, \[low\] conscientiousness, \[low\] agreeableness). Treatment will consist of six weekly 50-60-minute sessions. After the 6-week intervention period, participants will complete a 4-week follow-up period to determine the sustainability of effects observed
Study NCT06561022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abemaciclib
Description: Abemaciclib
Study NCT06561022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib
Study NCT05606744 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric exercise / Eccentric exercise with blood flow restriction
Description: Individuals will be randomized to receive eccentric exercise only, or eccentric exercise with blood flow restriction.
Study NCT05606744 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eccentric exercise / Eccentric exercise with blood flow restriction
Description: Individuals will be randomized to receive eccentric exercise only, or eccentric exercise with blood flow restriction.
Study NCT06037772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: subcutaneous injection administration game
Description: The subcutaneous injection practice game was developed to examine nursing students' injection practice skills and its effect on their satisfaction with learning.
Study NCT06037772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control group
Description: only
Study NCT05503901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STN1012600 ophthalmic solution 0.002%
Description: 1 drop STN1012600 ophthalmic solution 0.002% once daily for 52 weeks
Study NCT05503901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5%
Description: 1 drop STN1012600 ophthalmic solution 0.002% once daily for 52 weeks and 1 drop Timolol ophthalmic solution 0.5% twice daily for 52 weeks
Study NCT06036004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal OXT
Description: Syntocinon® contains the synthesized peptide OXT in a solution formulated to promote absorption through the nasal mucosa. Additional ingredients are E216 (propyl-4-hydroxybenzoate), E218 (methyl-4-hydroxybenzoate), and chlorobutanol hemihydrate. One bottle contains 5 ml, i.e., 200 IU of OXT in total. Each 0.1 ml nasal insulation delivers 4 IU of oxytocin.~OXT (24 IU twice daily) is given for 28 (± 2) days of treatment.
Study NCT06036004 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: The placebo will contain no OXT but, otherwise, be identical to the intranasal OXT product with respect to the other ingredients.~Placebo is given twice daily for 28 (± 2) days of treatment.
Study NCT05418309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab Nab paclitaxel
Description: Tislelizumab 200mg will be administered on Day 1 of each cycle for 4 treatment cycles;Nab-paclitaxel 200mg will be administered on Day 2 of each cycle for 4 treatment cycles.
Study NCT06037772 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: only
Study NCT06449937 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical local Surgery
Description: Radical local resection of liver metastases ( hepatectomy, ablation )
Study NCT06449937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic therapy
Description: Chemotherapy, targeted drug therapy, immunotherapy treatment.
Study NCT06449937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic therapy
Description: Chemotherapy, targeted drug therapy, immunotherapy treatment.
Study NCT06449937 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interventional therapy
Description: Transcatheter arterial chemoembolization (TACE) Hepatic arterial infusion chemotherapy (HAIC)
Study NCT05145738 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: C-Raven with avatar
Description: Computer delivered intervention with the investigators' avatar; with linkage to community health worker.
Study NCT05145738 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: C-Raven without avatar
Description: Computer delivered intervention without the investigators' avatar; with linkage to community health worker.
Study NCT05996484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab, 240mg, IV., D1, every 3 weeks, 4 cycles.
Study NCT05996484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride
Description: Anlotinib Hydrochloride is a capsule in the form of 8 mg ,10 mg and 12 mg, orally, once daily, 2 weeks on/1 week off, every 3 weeks, 4 cycles.
Study NCT05996484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin paclitaxel
Description: Albumin paclitaxel, 200-260 mg/m2, IV., D1, every 3 weeks, 4 cycles.
Study NCT05996484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin, 60-75 mg/m2, IV., D1, every 3 weeks, 4 cycles.
Study NCT05059990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Intensity Aerobic Exercises Group
Description: Intervention Low Intensity Aerobic Exercises i.e. stationary cycle(supervised) Intensity 55-65% of HRmax Frequency 3 times a week Duration 30 min each session
Study NCT05059990 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Exercises Group
Description: Intervention Upper and lower limb ROM \& stretching exercises Intensity As per tolerance Frequency 12 repetition/4sets per exercise 3 times/week Duration 30 minutes each session
Study NCT04794283 — intervention group
Intervention type: OTHER
Intervention: Breast milk
Description: Milk substitute given during the first 24h
Study NCT04400617 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cross-sectional assessments to examine the relationship among sleep quality, functional/physical capacity, and cognitive performance.
Description: The first visit will consist of screening measurements. Participants will be asked to complete the following questionnaires: InterRAI Self Report Quality of Life Survey for Long Term Care Facilities (interRAI SQoL), Resident Assessment Instrument (RAI)-MDS 2.0, Global Physical Activity Questionnaire (GPAQ), Memory Complaint Questionnaire (MAC-Q), and Pittsburgh Sleep Quality Index (PSQI). At the end of this visit, the participants will be asked to wear the ActiWatch-2 (AW-2) as a wristwatch for 14 days. In the second visit, participants' height and weight will be measured and the participants will perform the following cognitive and functional tests: MoCA, Brief Visuospatial Memory Test-Revised (BVMT-R), Hopkins Verbal Learning Test-Revised (HVLT-R), Time up and Go (TUG), and Cognitive TUG (TUGcog). Finally, visit 3 will consist of on-site PSG recordings.
Study NCT04608214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisporivir
Description: Administration of alisporivir at the dose of 600 mg p.o. BID from D1 to D14 to patients and standard of care (SOC).
Study NCT04608214 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care (SOC)
Description: Locally accepted regimen protocols for patient care and select agents based on the underlying diagnosis and the severity of COVID 19 (excepting e.g. azithromycin and other antibiotics listed as prohibited medications)
Study NCT05589818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients will be treated with the standard dose of pembrolizumab for the first 12 weeks of the study. After week 12 assessments, patients without objective progression of disease are eligible to transition to Q6W dosing of pembrolizumab 400mg IV. Patients will be offered this schedule, also an FDA-approved option, at the discretion of the treating physician, based on tolerability of the q3week regimen and clinician assessment of need for closer follow up intervals. Pembrolizumab will be continued until disease progression, unacceptable toxicity, withdrawal of consent, or death.
Study NCT05704881 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: End-Tidal CO2 measurement during COPD exacerbation
Description: The EtCO2 will be measured at the emergency reception during assessment of vital signs by the nurse with the help of a mask or oxygen glasses measuring EtCO2. The patient will then be treated conventionally according to current international recommendations. The physician in charge of the patient will be blinded to this measurement. The outcome will be the initiation of invasive or non-invasive ventilation (NIV) within the first 24 hours of admission to the emergency department, as indicated by the physician in charge of the patient.
Study NCT06007937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Lorlatinib 100 mg orally daily
Study NCT06007937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab 10 mg/kg intravenous infusion once every three weeks is a tolerable and safe dose.
Study NCT04418921 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-regulation: MRehab - Un colegio emocionante, clinical trial with non-immersive virtual reality
Description: The principles of the programme will be based on the following premises for children with ASD: 1) Strengthening communicative attempts; 2) Choose the most natural contexts possible; 3) Establish structured and predictable routines and environments; 4)Visually support information; 5) Adapting our language to the understanding level of the child. On the difficulty of interpreting and responding to social emotions and cues, games of perspectives are of great interest, where the child and therapist describe the same object from different perspectives, beliefs (guess that may be in this box), games with social stories, which are short stories that use pictograms, to help understand especially situations with social ambiguity: 1) describing what happens; 2) orienting the action, indicating to the child what to do in that situation; 3) anticipating and explaining what can happen and how you can feel; 4) developing a strategy that can be applied in similar situations.
Study NCT05754632 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction using Delfi Personalized Tourniquet System
Description: The Delfi Tourniquet System is designed to be used in conjunction with exercise. The system automatically determines the degree of occlusion and allows for safe regulation of pressure. Patients will then complete exercises with the use of this device.
Study NCT04713709 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nasus Pharma FMXIN001
Description: A nasal spray of 4mg Naloxone Hydrochloride powder in a unit dose device
Study NCT04713709 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Nasus Pharma FMXIN001
Description: A nasal spray of 4mg Naloxone Hydrochloride powder in a unit dose device
Study NCT04713709 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nasal Naloxone liquid spray
Description: A nasal spray of 4mg/0.1mL Naloxone Hydrochloride solution in a unit dose device
Study NCT04713709 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Naloxone liquid spray
Description: A nasal spray of 4mg/0.1mL Naloxone Hydrochloride solution in a unit dose device
Study NCT05343143 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NeuraGen 3D Nerve Guide Matrix
Description: Integra NeuraGen 3D Nerve Guide Matrix is a resorbable implant for the repair of peripheral nerve gaps.
Study NCT06031857 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesio tape
Description: kinesio tape was applied over the specific muscle of rotator cuff
Study NCT06031857 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling
Description: dry needling was applied over the affected muscles
Study NCT04718545 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mucogingival surgery
Description: The gingival recession at mandibular incisor site will be covered by a gingival graft harvested from the palate.
Study NCT04718545 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mucogingival surgery
Description: The gingival recession at mandibular incisor site will be covered by a gingival graft harvested from the palate.
Study NCT04418921 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional self-regulation program
Description: The children from control group will follow a program of emotional education of Primary Schools, though group activities in the classroom .The content of the sessions will include 5 sessions of emotional awareness and 5 sessions of emotional and cognitive regulation.Each session will last 50 minutes
Study NCT06255873 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L- Carnitine
Description: L-carnitine was taken after feeds in the form of tablets or dissolved tablets in a dose of 50 mg/kg/day, with maximum dose of 2 g/day.
Study NCT06255873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ketogenic diet
Description: ketogenic diet (KD) initiated under supervision of expert physician who considered patient's age, type of feeding, needs and preferences of the child and his/her family to select the type and initial ratio of KD therapy, KD ratio ranged from 1:1 to 4:1 of lipids to carbohydrates plus proteins in grams.
Study NCT06255873 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ketogenic diet
Description: ketogenic diet (KD) initiated under supervision of expert physician who considered patient's age, type of feeding, needs and preferences of the child and his/her family to select the type and initial ratio of KD therapy, KD ratio ranged from 1:1 to 4:1 of lipids to carbohydrates plus proteins in grams.
Study NCT05941104 — intervention group
Intervention type: OTHER
Intervention: frailty
Description: Frailty is a group of common clinical syndromes in the elderly, characterized by systematic, dynamic and reversible, the core of which is the decline of physiological reserves and the destruction of self-balance.
Study NCT05522426 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SyntrFuge System
Description: Microsized Adipose Tissue
Study NCT06292871 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Additional GDM management through social media
Description: Usual care provided by a diabetes nurse educator and dietitian. Additional educational resources for dietary management care received, and for any queries to be addressed by dietitian via social media platform from baseline to one-month follow-up visit.
Study NCT06292871 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care provided by a diabetes nurse educator and dietitian.
Study NCT06292871 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual care provided by a diabetes nurse educator and dietitian.
Study NCT05827796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN10018
Description: IN10018 orally once daily at approximately the same time each day, to ensure a dosing interval of approximately 24 hours.
Study NCT05827796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel
Description: Albumin-bound paclitaxel will be administered as per the schedule specified in the respective arm.
Study NCT05827796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered as per the schedule specified in the respective arm.
Study NCT05827796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN046
Description: KN046 5 mg/kg on Day 1 of each 21-Day Cycle.
Study NCT05585255 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: enzyme-linked immunosorbent assay(ELISA)
Description: After allowing to stand at room temperature for 2h, blood samples are centrifuged at 4 ℃ for 15 min (12000 rpm) to collect the supernatant. Then, the levels of DKK2, IL-6, IL-1β, TNF-α, and IL-10 in the supernatants are tested by ELISA detection.
Study NCT06299943 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biofeedback gait training by biomechanical target parameter
Description: The patient walks using a treadmill at a comfortable speed until he gets tired. The patient is instructed that when performing a virtual task (in a virtual environment on the screen), his walking will be harmonized (without informing him on what parameter). If it fails to cope, then the zones of permissible changes (on the information columns) will expand, and the virtual task will signal its incomplete completion.
Study NCT05491759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Product 1 - AquaCelle Fish Oil Triglyceride
Description: 1 dose of 2 capsules equivalent to 1.6g Fish Oil Triglyceride (standardised to contain 1120 mg of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA)) and 0.4g AquaCelle.
Study NCT05491759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Product 2 - AquaCelle Fish Oil Ethyl Ester
Description: 1 dose of 2 capsules equivalent to 1.6g Fish Oil Ethyl Ester (standardised to contain 1120 mg of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA)) and 0.28g AquaCelle
Study NCT05491759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Product 3 - Standard Fish Oil Triglyceride
Description: 1 dose of 2 capsules equivalent to 1.6g Fish Oil Triglyceride (standardised to contain 1120 mg of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA)).
Study NCT05168670 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Protection of eyes with tinted soft scleral eye shields
Description: In subjects with dry eye disease due to meibomian gland dysfunction, protection of eyes with tinted soft scleral eye shields followed by IPL administration on eyelids